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Abstract
EUCAST expert rules have been developed to assist clinical microbiologists and describe actions to be taken in response to speciﬁc
antimicrobial susceptibility test results. They include recommendations on reporting, such as inferring susceptibility to other agents from
results with one, suppression of results that may be inappropriate, and editing of results from susceptible to intermediate or resistant
or from intermediate to resistant on the basis of an inferred resistance mechanism. They are based on current clinical and/or microbio-
logical evidence. EUCAST expert rules also include intrinsic resistance phenotypes and exceptional resistance phenotypes, which have
not yet been reported or are very rare. The applicability of EUCAST expert rules depends on the MIC breakpoints used to deﬁne the
rules. Setting appropriate clinical breakpoints, based on treating patients and not on the detection of resistance mechanisms, may lead
to modiﬁcation of some expert rules in the future.
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Introduction
Antimicrobial susceptibility testing is a daily task in clinical
microbiology laboratories worldwide. In view of the
increasing complexity and widespread increase in antimi-
crobial resistance mechanisms and the clinical implications
of the resistance, expert knowledge is desirable for inter-
pretation of tests. An expert rule in antimicrobial suscep-
tibility testing describes an action to be taken on the
basis of speciﬁc antimicrobial susceptibility test results.
The rules are based on current clinical breakpoints and
knowledge of resistance mechanisms. Expert rules for
antimicrobial susceptibility testing can assist clinical micro-
biologists in the interpretation of antimicrobial susceptibil-
ity tests [1], but, with changes in breakpoints and the
discovery of new resistance mechanisms, rules may
become redundant or require modiﬁcation. Rules can also
contribute to quality assurance by highlighting anomalous
or unlikely results [2–5]. The EUCAST expert rules in
antimicrobial susceptibility testing, ﬁrst published in 2008
(http://www.eucast.org), are divided into intrinsic resis-
tance, exceptional phenotypes, and interpretive rules. In
this document, we present the second version of these
rules, which has been updated in line with current EU-
CAST breakpoints.
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REVIEW BACTERIOLOGY
Intrinsic Resistance
Intrinsic (inherent) resistance, as opposed to acquired and/or
mutational resistance, is a characteristic of all or almost all iso-
lates of the bacterial species. The antimicrobial activity of the
drug is clinically insufﬁcient or antimicrobial resistance is
innate, rendering it clinically useless. Antimicrobial susceptibil-
ity testing is therefore unnecessary, although it may be per-
formed as part of panels of test agents. In these species,
‘susceptible’ results should be viewed with caution, as they
most likely indicate an error in identiﬁcation or susceptibility
testing. Even if a susceptible result is conﬁrmed, the drug
should preferably not be used or, when no alternative is avail-
able, should be used with caution. In some cases, intrinsic
resistance to an agent may be expressed at a low level, with
MIC values close to the susceptible breakpoint, although the
agent is not considered to be clinically active. There are also
situations where the agent appears to be fully active in vitro
(MIC values cannot be separated from those of the wild type)
but is inactive in vivo. These are generally not mentioned in the
tables, as they are rather a matter of therapeutic recommen-
dations. Examples of intrinsic resistance are Enterobacteriaceae
resistant to glycopeptides or linezolid, Proteus mirabilis resis-
tant to nitrofurantoin and colistin, Serratia marcescens resistant
to colistin, Stenotrophomonas maltophilia resistant to carbapen-
ems, Gram-positive organisms resistant to aztreonam, and
enterococci resistant to fusidic acid (Tables 1–4).
Exceptional Resistance Phenotypes
Exceptional resistance phenotypes are phenotypes of resistance
of some bacterial species to particular antimicrobial agents that
have not yet been reported or are very rare. Exceptional resis-
tance phenotypes should be checked, as they may also indicate
an error in identiﬁcation or susceptibility testing. If they are
conﬁrmed locally, the isolate should be further studied to con-
ﬁrm the exceptional phenotype, and sent to a reference labora-
tory or other laboratory with expertise in resistance
mechanisms for independent conﬁrmation. Exceptional resis-
tance phenotypes may change, as resistance may develop and
increase over time. There may also be local, regional or
national differences, and a very rare resistance phenotype in
one hospital, area or country may be more common in
another. Examples of exceptional phenotypes are Streptococcus
pyogenes resistant to penicillin, Staphylococcus aureus resistant
to vancomycin, Enterococcus faecium susceptible to ampicillin,
Enterobacteriaceae resistant to carbapenems (rare but increas-
ing), and anaerobes resistant to metronidazole (Tables 5–7). T
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Interpretive Reading and Expert Rules
Interpretive reading is another type of expert rule, and
involves inference of resistance mechanisms from susceptibil-
ity test results, and interpretation of clinical susceptibility on
the basis of the resistance mechanism [1–4]. The applicability
of such rules is limited by the range of agents tested, so indi-
vidual laboratories will need to choose which agents to test
for their local requirements. The applicability of any rule will
also depend on the MIC breakpoints used to deﬁne the rule.
EUCAST interpretive rules may be simple—for example, IF
S. aureus is resistant to oxacillin or cefoxitin, THEN report
as resistant to all b-lactams—or more complicated—for
example, IF Enterobacteriaceae are intermediate to tobramy-
cin, resistant to gentamicin, and susceptible to amikacin,
THEN report as resistant to tobramycin. The evidence sup-
porting interpretive rules is often not conclusive, and there
may be differences of opinion regarding the most appropriate
clinical action. Hence, these rules should be based on cur-
rent published evidence, the quality of evidence should be
assessed, and exceptions to any rules should be noted. In
the EUCAST tables (Tables 8–13), the evidence for rules has
been graded as follows:
1. There is good clinical evidence that reporting the test
result as susceptible leads to clinical failures.
2. Evidence is weak and based on only a few case reports
or on experimental models. It is presumed that report-
ing the test result as susceptible may lead to clinical
failures.
3. There is no clinical evidence, but microbiological data
suggest that clinical use of the agent should be discour-
aged.
Actions to be taken by laboratories on the basis of EUCAST
expert rules include recommendations on reporting, such as
inferring susceptibility to other agents from results with one,
suppression of results that may be inappropriate, and editing
of results from susceptible to intermediate/resistant or from
intermediate to resistant on the basis of an inferred resis-
tance mechanism. Rules never recommend editing intermedi-
ate or resistant to susceptible or resistant to intermediate,
because even if resistance has never been reported, there
may be new resistance mechanisms that have not been previ-
ously recognized, and treatment is likely to fail. Comments
may also be added to explain actions or warn of resistance
of particular epidemiological signiﬁcance. Advice may be
given on further tests that may be appropriate or on the
need for referral of isolates to a reference laboratory for
checking susceptibility or identiﬁcation.
Application of EUCAST expert rules may impose some
testing requirements on clinical laboratories. Many rules
require the full identiﬁcation of the organism even if it is not
essential for clinical management. There may be a need to
test an extended range of appropriate agents, as interpretive
rules may require testing of agents that may not be required
clinically. There is also a clinical need for access to a set of
expert rules, as there are many expert rules, and few individ-
uals are able to remember them all and to apply them con-
sistently.
There are few publications on expert rules, and these
are more likely to be used as a reference source than for
everyday application [1,4]. The wide range of expert rules
means that they are only likely to be applied consistently
and widely if they are available as a published set of rules
that can be incorporated into computer systems. Rules may
be incorporated into a laboratory information system (LIS),
but this is limited by the capabilities of the LIS and the abil-
ity and interest of individual laboratories in incorporating
rules into the LIS. Expert systems are, however, incorpo-
rated into several automated susceptibility and zone reading
systems.
The purpose of the EUCAST expert rules is to provide a
written description of current expert rules. The rules are a
comprehensive collection that may be applied manually or
incorporated into automated systems [6,7]. The rules were
TABLE 3. Intrinsic resistance in Gram-negative bacteria other than Enterobacteriaceae and non-fermentative Gram-negative
bacteria; Gram-negative bacteria other than Enterobacteriaceae and non-fermentative Gram-negative bacteria listed are also
intrinsically resistant to glycopeptides, lincosamides, daptomycin, and linezolid
Rule no. Organisms Macrolides Fusidic acid Streptogramins Trimethoprim Nalidixic acid
3.1 Haemophilus inﬂuenzae I R – – –
3.2 Moraxella catarrhalis – – – R –
3.3 Neisseria spp. – – – R –
3.4 Campylobacter fetus – R R R R
3.5 Campylobacter jejuni, Campylobacter coli – R R R –
R, resistant; I, intermediate.
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prepared by an expert subcommittee in consultation with
European national susceptibility breakpoint committees,
EUCAST national representatives, the pharmaceutical and sus-
ceptibility device-manufacturing industries, recognized experts,
and others via open consultation through the EUCAST web-
site. Rules should not conﬂict with EUCAST MIC breakpoints,
but it is appreciated that some antimicrobial agents are not
included in EUCAST breakpoints, and many rules have devel-
oped over the years in conjunction with other breakpoint
systems. Hence, rules are likely to be amended as EUCAST
breakpoints are developed and in the light of experience
with application of the rules and the emergence of new
resistance mechanisms. This second version will undoubtedly
need to be updated again in the future.
Explanatory Notes on EUCAST Expert
Rules in Antimicrobial Susceptibility Testing
The EUCAST Expert Rules Subcommittee was established in
2007 with the objective of assisting clinical microbiologists in
the interpretation of antimicrobial susceptibility tests beyond
interpretation of in vitro tests for the assignment of clinical
categories of antimicrobial susceptibility. For this purpose,
different rules have been produced, including those deﬁning
intrinsic resistance and exceptional phenotypes as well as
interpretive rules. The latter are structured in tables
(Tables 8–13 of EUCAST Expert Rules in Antimicrobial Sus-
ceptibility Testing) that group different organisms and/or
classes of antimicrobial agents. They were mainly established
by use of EUCAST MIC breakpoints to deﬁne the clinical
categories (susceptible, intermediate, or resistant) included
in the expert rule statement. These rules should be applied
once the bacterial isolates have been identiﬁed to species
level. Although recognition of the resistance mechanisms is
an essential part of the interpretive expert rule, the ﬁnal
objective is to assist in the clinical use of antimicrobial
agents.
Interpretive rules for b-lactam agents
b-Lactam compounds are the most widely used antimicro-
bial agents. They interact with the penicillin-binding proteins
(PBPs), which are the enzymes involved in the terminal
stages of peptidoglycan synthesis, and exert a bactericidal
effect because of a subsequent imbalance of cell wall auto-
lytic enzymes. Resistance to these compounds is mainly
caused by b-lactamases, which constitute a large family of
different hydrolases that disrupt and inactivate the b-lactam
structure. These enzymes variably affect different b-lactam
compounds, thus producing different phenotypes and/or lev-
els of resistance, particularly in Gram-negative bacilli [8,9].
In addition, target (PBP) modiﬁcation may compromise b-
TABLE 5. Exceptional phenotypes of Gram-negative bacte-
ria
Rule
no.
Organisms Exceptional phenotypes
5.1 Any Enterobacteriaceae
(except Proteae)
Resistant to meropenem and/or
imipenema
5.2 Serratia marcescens
and Proteae
Susceptible to colistin
5.3 Pseudomonas aeruginosa
and Acinetobacter spp.
Resistant to colistin
5.4 Haemophilus inﬂuenze Resistant to any third-generation
cephalosporin, carbapenems, and
ﬂuoroquinolones
5.5 Moraxella catarrhalis Resistant to ciproﬂoxacin and any
third-generation cephalosporin
5.6 Neisseria meningitidis Resistant to any third-generation
cephalosporin and ﬂuoroquinolones
5.7 Neisseria gonorrhoeae Resistant to third-generation
cephalosporin and spectinomycin
aExcept in countries in which carbapenemase-producing Enterobacteriaceae are
not rare.
TABLE 6. Exceptional phenotypes of Gram-positive bacteria
Rule no. Organisms Exceptional phenotypes
6.1 Staphylococcus aureus Resistant to vancomycin, teicoplanin, linezolid, quinupristin–dalfopristin, daptomycin, and tigecycline
6.2 Coagulase-negative staphylococci Resistant to vancomycin, linezolida, quinupristin–dalfopristina, daptomycin, and tigecycline
6.3 JK coryneform organisms Resistant to vancomycin, teicoplanin, linezolid, quinupristin–dalfopristin, daptomycin, and tigecycline
6.4 Streptococcus pneumoniae Resistant to imipenem, meropenem, vancomycin, teicoplanin, linezolid, quinupristin–dalfopristin, daptomycin,
tigecycline, and rifampicin
6.5 Group A, B, C and G b-haemolytic
streptococci
Resistant to penicillin, cephalosporins, vancomycin, teicoplanin, linezolid, quinupristin–dalfopristin, daptomycin,
and tigecycline
6.6 Enterococcus spp. Resistant to linezolid, daptomycin, and tigecycline. Resistant to teicoplanin but not vancomycin
6.7 Enterococcus faecalis, Enterococcus
gallinarum, Enterococcus casseliﬂavus,
and Enterococcus avium
Susceptible to quinupristin–dalfopristin. Consider likelihood of misidentiﬁcation. If also resistant to ampicillin,
it is almost certainly E. faecium
6.8 Enterococcus faecium Resistant to quinupristin–dalfopristin. Consider likelihood of misidentiﬁcation, especially if also susceptible
to ampicillin
aExcept in countries where linezolid-resistant or quinupristin–dalfopristin-resistant coagulase-negative staphylococci are not rare.
TABLE 7. Exceptional phenotypes of anaerobes
Rule no. Organisms Exceptional phenotypes
7.1 Bacteroides spp. Resistant to metronidazole and carbapenems
7.2 Clostridium difﬁcile Resistant to metronidazole and vancomycin
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lactam activity. This mechanism is encountered particularly
in Gram-positive cocci. The contribution of PBP modiﬁca-
tion to b-lactam resistance in Gram-negative organisms is
generally less important [10]. Porin modiﬁcations and efﬂux
pump hyperexpression in Gram-negative organisms may also
compromise b-lactam compounds, but the resistance levels
conferred by these mechanisms alone are commonly lower
than those observed with resistance conferred by most
b-lactamases [11,12]. EUCAST expert rules for b-lactams
and Gram-positive cocci are focused on staphylococci,
streptococci, including b-haemolytic isolates, viridans group
streptococci, Streptococcus pneumoniae, and enteroccocci
(Table 8).
Staphylococci . Production of penicillinase in staphylococci is
very common (>90% of the S. aureus isolates in many coun-
tries) and leads to phenotypic resistance to all penicillins
except the isoxazolyl analogues (rule 8.2). Staphylococci can
also be resistant to the isoxazolyl penicillins, owing to the
production of an abnormal PBP (PBP2a encoded by mecA),
leading to cross-resistance to all b-lactams except for a few
with low afﬁnity for PBP2a (rule 8.1) [13]. Resistance medi-
ated by mecA is commonly referred to as methicillin (or oxa-
cillin) resistance, as historically these agents have been widely
used for in vitro testing. Detection of methicillin resistance is
mandatory in S. aureus clinical isolates [14]. All staphylococci
resistant to methicillin, oxacillin, and/or cefoxitin, or with
positive test results for mecA or PBP2a, should be considered
to be resistant to all available b-lactams [15], with the excep-
tion of those speciﬁcally licensed for the treatment of infec-
tions caused by methicillin-resistant staphylococci.
Nevertheless, rare penicillinase hyperproduction may result
in borderline resistance to oxacillin (but not cefoxitin) in vitro,
owing to the lability of oxacillin, but there is no evidence that
penicillinase hyperproduction is clinically relevant [16].
Streptococci . Among b-haemolytic streptococci, susceptibility
to penicillins is currently the rule. No decreased susceptibil-
TABLE 10. Interpretive rules for b-lactam agents and other Gram-negative bacteria
Rule
no.
Organisms Agents
tested
Agents affected Rule Exceptions, scientiﬁc
basis, and comments
Evidence
grade
References
10.1 Haemophilus
inﬂuenzae
Ampicillin or
amoxycillin (and
b-lactamase
detection)
Ampicillin, amoxycillin,
and piperacillin
IF b-lactamase-positive,
THEN report as resistant
to ampicillin, amoxycillin,
and piperacillin
Ampicillin is the class
representative for amoxycillin.
Resistance to ampicillin by
production of b-lactamase may
be misidentiﬁed by the disk
diffusion technique. Production
of b-lactamase should be
examined with a chromogenic
test
A [106,107]
10.2 Haemophilus
inﬂuenzae
Ampicillin or
amoxycillin (and
b-lactamase
detection)
Ampicillin, amoxycillin,
amoxycillin–clavulanate,
ampicillin–sulbactam,
cefaclor, cefuroxime,
cefuroxime axetil,
piperacillin, and
piperacillin–tazobactam
IF b-lactamase-negative but
ampicillin-resistant (BLNAR),
THEN report as resistant to
ampicillin, amoxycillin,
amoxycillin–clavulanate,
ampicillin–sulbactam,
piperacillin, piperacillin–
tazobactam, cefaclor,
cefuroxime, and cefuroxime
axetil
BLNAR isolates have reduced
afﬁnity of PBPs for b-lactams.
Although piperacillin and
piperacillin–tazobactam appear
to be less affected by the
PBP-mediated resistance
mechanisms, evidence regarding
clinical efﬁcacy is lacking
C [48,49,108]
10.3 Haemophilus
inﬂuenzae
Amoxycillin–
clavulanate (and
b-lactamase
detection)
Ampicillin–sulbactam,
cefaclor, cefuroxime,
cefuroxime axetil,
piperacillin, and
piperacillin–tazobactam
IF b-lactamase-positive and
amoxycillin–clavulanate-
resistant (BLPACR), THEN
report as resistant to
ampicillin, amoxycillin,
amoxycillin–clavulanate,
ampicillin–sulbactam,
cefaclor, piperacillin,
piperacillin–tazobactam,
cefuroxime, and cefuroxime
axetil
BLPACR isolates produce
b-lactamase and have reduced
afﬁnity of PBPs for b-lactams.
Although piperacillin and
piperacillin–tazobactam appear
to be less affected by the
PBP-mediated resistance
mechanisms, evidence regarding
clinical efﬁcacy is lacking
C [48,108]
10.4 Neisseria
gonorrhoeae
Benzylpenicillin,
ampicillin, or
amoxycillin (and
b-lactamase
detection)
Benzylpenicillin,
ampicillin, and
amoxycillin
IF positive for production of
b-lactamase, THEN report
as resistant to
benzylpenicillin, ampicillin,
and amoxycillin
Penicillin resistance can be
caused by plasmid-encoded
b-lactamase production
(TEM-1). Chromosomal
mutations affecting afﬁnity for
PBPs, decreased permeability or
efﬂux also confer resistance to
b-lactamase inhibitor
combinations. Penicillin
susceptibility in b-lactamase-
negative isolates is indicated by
the application of breakpoints
A [55–57]
PBP, penicillin-binding protein.
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ity to b-lactams has been reported except in group B strep-
tococci (MIC of benzylpenicillin up to 1 mg/L) [17]. Isolates
susceptible to penicillin can be reported as susceptible to
aminopenicillins, cephalosporins, and carbapenems [18]. If an
isolate is resistant to penicillin, identiﬁcation and susceptibil-
ity should be checked (rule 8.3). Conversely, resistance to b-
lactams in Streptococcus pneumoniae is common, owing to the
production of mosaic PBPs that lead to various patterns of
b-lactam resistance [19]. The oxacillin disk is traditionally
used in screening tests to indicate benzylpenicillin susceptibil-
ity. Nevertheless, in addition to benzylpenicillin, when clini-
cally needed, MICs of cephalosporins and carbapenems
should be determined when the isolate is benzylpenicillin-
resistant or when the oxacillin disk diffusion screening test
result is interpreted as indicating resistance (rule 8.4).
Among viridans group streptococci, production of mosaic
PBPs also leads to various patterns of b-lactam resistance,
and the oxacillin disk diffusion test developed for Streptococ-
cus pneumoniae shows inadequate sensitivity in prediction of
penicillin susceptibility. Moreover, susceptibility to cephalo-
sporins and carbapenems cannot be inferred from benzylpen-
icillin susceptibility (rule 8.5) [20].
Enterococci . All enterococci are considered to be intrinsically
resistant to cephalosporins (Table 4), but resistance to ampi-
cillin mediated by alterations to PBP5 is increasingly recog-
nized, particularly in E. faecium [21]. These alterations lead
to decreased afﬁnity for b-lactams, including all penicillins
and carbapenems (rule 8.6). Penicillinase-producing Enterococ-
cus isolates have been rarely detected, but have recently
been described in Europe [22] (Sarti et al., 51st ICACC,
2011, Abstract C1-1785).
Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter
spp . Interpretive reading of the antibiogram is commonly
based on b-lactams and b-lactamases in Gram-negative bacilli
[8]. The ﬁrst version of EUCAST expert rules for b-lactams
and Enterobacteriaceae was inﬂuenced by this, particularly with
isolates producing extended-spectrum b-lactamases (ESBLs)
or carbapenemases. The cephalosporin and carbapenem
breakpoints available when ﬁrst version of EUCAST expert
rules was published were later considered inappropriate, and
old expert rules addressing ESBL and carbapenemase produc-
ers therefore needed to be modiﬁed in the second version of
the rules.
For many years, conﬁrmatory tests, mainly based on the
synergistic effect observed between cephalosporins and b-
lactamase inhibitors such as clavulanate, were applied in clini-
cal microbiology laboratories to indicate the presence of
ESBLs, mainly in Escherichia coli and Klebsiella pneumoniae iso-
lates with reduced susceptibility to oxyimino-cephalosporins
[23–25]. Following the detection of ESBL production in an
isolate, the susceptible and intermediate categories were
reinterpreted as resistant on the assumption that the break-
points were inadequate. However, some authors claimed
that MIC breakpoints set at appropriate levels (decreasing
their values) can detect the presence of ‘clinically signiﬁcant’
resistance mechanisms, including ESBLs [26]. Animal models,
pharmacokinetic (PK)/pharmacodynamic (PD) analysis, Monte
Carlo simulation and new lower EUCAST breakpoints sup-
ported this approach. It is possible to avoid classiﬁcation of
most ESBL producers as susceptible to oxyimino-cephalospo-
rins (mainly ceftazidime and cefepime) and aztreonam with
EUCAST breakpoints as compared with CLSI breakpoints
[27,28]. In addition, reduction in breakpoints so that clinically
signiﬁcant resistance is detected without the need for conﬁr-
matory tests avoids possible delay in reporting of susceptibil-
ity testing results for a large proportion of isolates, as the
prevalence of ESBL-producing organisms has increased.
Most traditional microbiological practices have considered
that all conﬁrmed ESBL-positive organisms are resistant to
all penicillins, cephalosporins, and aztreonam, thus forcing
overuse of other antimicrobial classes such as carbapenems
and ﬂuoroquinolones. This, in turn, potentially exerts a selec-
tive pressure on microorganisms with other antimicrobial
resistance mechanisms, including carbapenemase producers.
Although clinical outcome with the use of third-generation
and fourth-generation cephalosporins in the treatment of
infections caused by low-MIC, ESBL-positive microorganisms
remains to be fully evaluated, the new EUCAST breakpoints
leave some room for the use of cefotaxime, ceftriaxone, or
ceftazidime. This is supported by several clinical studies and
observations, PK/PD data, Monte Carlo simulations, and ani-
mal model studies [29–34]. These studies have shown that
clinical and experimental outcomes are better correlated
with the MIC values than with the presence of an ESBL.
With the new EUCAST breakpoints for Enterobacteriaceae,
third-generation and fourth-generation cephalosporins should
be reported as found, and the old expert rule recommending
modiﬁcation of reporting category for ESBL producers that
appear to be susceptible is no longer necessary. This recom-
mendation, which also applies to plasmid-mediated AmpC
producers, is now included in the EUCAST breakpoint
tables. Nevertheless, in many areas, ESBL detection and char-
acterization are recommended or mandatory for infection
control purposes. For consistency, and based on a similar
approach, other rules, including those affecting Klebsiella oxyt-
oca and Citrobacter koseri (old expert rule 9.3) [35] and that
for isolates with carbapenemases (old expert rule 9.7), are
deleted in the second version of the expert rules.
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Carbapenemases, including class A, B and D enzymes, can
have variable effects on carbapenems [36–38]. Moreover,
combined resistance mechanisms may also affect carbapenem
susceptibility (e.g. combination of derepressed AmpC or
ESBL and decreased permeability), ertapenem being particu-
larly affected [39]. Recent data, as with ESBL producers, pro-
vide evidence to support the reporting of carbapenem
susceptibility as found [40,41]. Nevertheless, more effort is
required in the future to expand the evidence, particularly
when a carbapenemase with low-level expression, such as
with VIM enzymes, is present [42]. It is important to note
that special attention should be paid to reduced susceptibility
to carbapenems that may be related to true carbapenemases,
not only for producers of class B (mainly VIM or IMP) or
class A carbapenemases (KPC), but also for those expressing
OXA-48, a class D carbapenemase that is increasingly being
identiﬁed in Enterobacteriaceae [43].
New expert rule number 9.1 highlights the uncertain ther-
apeutic outcome of treatment with a penicillin in combina-
tion with a b-lactamase inhibitor for Enterobacteriaceae
isolates that are intermediate or resistant to any third-gener-
ation or fourth-generation cephalosporin in infections other
than those affecting the urinary tract [44,45]. This is also the
case for new expert rule number 9.2, the evidence for which
is graded A for Enterobacter spp. and B for Citrobacter freundii,
Serratia spp., and Morganella morganii. Rule 9.2 recommends
discouraging the use of cefotaxime, ceftriaxone or ceftazi-
dime in monotherapy or suppressing the susceptibility testing
results for these agents, owing to the risk of selecting resis-
tance in AmpC producers [46]. In some publications, it is
claimed that this problem can be avoided with combination
therapy, including (unlike aminoglycosides) the addition of a
ﬂuoroquinolone [47].
Other Gram-negative organisms . Other Gram-negative organ-
isms, such as Haemophilus inﬂuenzae and Neisseria gonor-
rhoeae, are considered in the EUCAST expert rules
Table 10. For H. inﬂuenzae, resistance to ampicillin, which is
considered representative of amoxycillin for susceptibility
testing, is mainly attributable to b-lactamase production. Iso-
lates producing b-lactamases, mainly TEM-1, should be con-
sidered to be resistant to both ampicillin and amoxycillin
(rules 10.1) [48]. Ampicillin resistance in the absence of
b-lactamase production can be conferred by mutations in the
ftsI gene affecting PBPs and leading to reduced afﬁnity for
b-lactams [49]. These isolates, termed b-lactamase-negative
and ampicillin-resistant, should be considered to be resistant
to aminopenicillin–b-lactamase inhibitor combinations (amox-
ycillin–clavulanate, ampicillin–sulbactam, and piperacillin–tazo-
bactam) and to ﬁrst-generation and second-generation
cephalosporins (rule 10.2) [50,51]. Although piperacillin and
piperacillin–tazobactam appear less affected by the PBP-
mediated resistance mechanisms, evidence regarding clinical
efﬁcacy is lacking.
H. inﬂuenzae isolates with altered PBPs and b-lactamase
production are also being increasingly found. These isolates
are phenotypically resistant to amoxycillin–clavulanate and
ampicillin–sulbactam (b-lactamase-positive and resistant to
amoxycillin–clavulanate, and should also be considered to be
resistant to piperacillin–tazobactam and to ﬁrst-generation
and second-generation cephalosporins (rule 10.3) [52]. ESBL-
producing isolates have not yet been found in H. inﬂuenzae,
but blaESBL genes have been cloned in this species, resulting
in third-generation cephalosporin resistance when PBP3 is
concomitantly altered [53]. Moreover, a TEM ESBL variant
has also been found in Haemophilus parainﬂuenzae [54].
For N. gonorrhoeae, isolates that are b-lactamase-positive
should be considered to be resistant to benzylpenicillin,
ampicillin, and amoxycillin. Chromosomal mutations affecting
afﬁnity of PBPs, decreased permeability or efﬂux pumps also
confer resistance to b-lactamase inhibitor combinations, and
resistance will be detected by the application of EUCAST
breakpoints (rule 10.4) [55–57].
Expert rules for Moraxella catarrhalis have been deleted in
this second version of the expert rules, and the relevant
points are now included in the breakpoint table.
Interpretive rules for macrolides, lincosamides, and strep-
togramins
Although the macrolides, lincosamides and streptogramins
have different chemical structures, they share similar mecha-
nisms of action, and can be affected by the same resistance
mechanisms. EUCAST expert rules for these agents include
staphylococci, streptococci, Peptostreptococcus spp., and Bacte-
roides spp. (Table 11, rules 11.1–11.5). Other organisms, such
as H. inﬂuenzae, have been considered in this version of the
expert rules only within the intrinsic resistance tables.
Erythromycin is considered to be the class representative
for 14-membered (clarithromycin) and 15-membered (azi-
thromycin) ring macrolides, with the exception of ketolides
(telithromycin). Resistance to these compounds is generally
mediated by the production of ribosomal methylases
encoded by erm genes that confer constitutive or inducible
macrolide–lincosamide–streptogramin B (MLSB) phenotypes
or by the production of an efﬂux pump (M phenotype, con-
ferring resistance to erythromycin but not to clindamycin
and/or streptogramins) [58]. With both mechanisms, there is
cross-resistance between erythromycin and the other 14-
membered and 15-membered ring macrolides (rule 11.1).
This resistance can occur with or without cross-resistance
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to clindamycin and lincosamides. For staphylococci and strep-
tococci, isolates resistant to erythromycin but susceptible to
clindamycin should be tested for inducible MLSB resistance
(dissociated resistance) [58].
The recommended disk diffusion test for inducible MLSB
resistance consists of an erythromycin disk in close proxim-
ity to a clindamycin disk. Flattening of the zone of inhibition
around the clindamycin or lincosamide disk in the vicinity of
erythromycin (‘D’-shaped zone) is indicative of the inducible
MLSB phenotype, which is mediated by the presence of an
erm gene. A negative result, i.e. no ﬂattened zone, is associ-
ated with the presence of an efﬂux pump (mef gene). From a
clinical point of view, the use of clindamycin or lincomycin is
not recommended in infections caused by isolates displaying
an inducible MLSB phenotype. These isolates should be
reported as resistant or with a warning indicating potential
clinical failure during treatment with clindamycin or lincomy-
cin (rule 11.2) [59]. For staphylococcal isolates that are
simultaneously resistant to erythromycin and clindamycin or
lincomycin, a warning of reduced susceptibility to the combi-
nation quinupristin–dalfopristin and loss of bactericidal activ-
ity should be included in the susceptibility test report
(rule 11.5) [60,61].
For streptococci, less clinical evidence is available but, sim-
ilarly, isolates that are resistant to erythromycin and suscep-
tible to clindamycin should be tested for inducible MLSB
resistance and reported as clindamycin-susceptible if the
result is positive but with a warning that resistance may
develop on prolonged treatment (rule 11.3) [58]. When Pe-
ptostreptococcus spp. and Bacteroides spp. express an inducible
MLSB phenotype, resistance to clindamycin is difﬁcult to
detect in vitro, and this agent should not be considered to be
clinically active (rule 11.4) [62,63].
Interpretive rules for aminoglycosides
Aminoglycoside agents have a bactericidal effect on most
Gram-positive and Gram-negative organisms. They bind to
16S rRNA of the 30S bacterial ribosomal subunit and thereby
inhibit protein synthesis. Several mechanisms that compro-
mise the activity of aminoglycosides have been described: (i)
decreased permeability and/or accumulation of the aminogly-
coside agents because of mutations affecting passive diffusion
or active transport, porin and/or lipopolysaccharide alteration
(only in Gram-negative organisms), and efﬂux pump hyperex-
pression; (ii) target (ribosomal) modiﬁcations caued by muta-
tions in ribosomal proteins (S3, S4, S5, S6, S12, S17, and L6)
and as a result of the action of new methylases affecting 16S
RNA; and (iii) aminoglycoside-modifying enzymes, which are
acetyltransferases, phosphotransferases, or nucleotidyltransfe-
rases (also known as adenylyltransferases) [64–68].
Phenotype recognition of these resistance mechanisms is
generally more complex than for those affecting b-lactam
compounds. Decreased permeability and/or resistance mech-
anisms involving efﬂux pumps usually confer a low-level resis-
tance phenotype affecting nearly all aminoglycosides. With
the exception of those described in P. aeruginosa, resistance
mediated by efﬂux pumps is difﬁcult to infer from phenotypic
susceptibility [68], but cross-resistance to other antimicrobial
classes, such as ﬂuoroquinolone or tetracycline agents, might
indicate their potential presence. Ribosomal mutations are
extremely rare, do not confer ‘class resistance’, and do not
always endow high-level resistance. Conversely, 16S RNA
methylation confers high-level resistance, mainly affecting 4,6-
disubstituted compounds (such as kanamycin, gentamicin, tob-
ramycin, amikacin, and netilmicin), but not 4,5-disubstituted
compounds (such as neomycin and paramomycin), streptomy-
cin, and/or the aminocyclitol agent spectinomycin [69].
Aminoglycoside-modifying enzymes are the most widely
distributed resistance mechanisms affecting aminoglycosides,
and enzymatic modiﬁcation of an aminoglycoside can be
mediated by different enzymes. Modiﬁcations do not always
confer phenotypic resistance, and resistance may be more
clearly indicated in tests with aminoglycoside agents that are
not used in the human clinical setting [69–72]. Other prob-
lems complicating interpretive reading for this group of anti-
microbials are that enzymatic modiﬁcations of different
aminoglycosides can be produced by a single enzyme and
that unrelated enzymes can confer a similar resistance phe-
notype. Also, a single isolate can express different modifying
enzymes, making interpretation of resistance phenotypes dif-
ﬁcult and, in some cases, unreliable.
Despite this apparent complexity, several EUCAST inter-
pretive rules can be applied when antibiograms of aminogly-
cosides are read (Table 12). For Gram-positive organisms,
these rules facilitate detection of the absence of synergy
between a speciﬁc aminoglycoside and b-lactam or glycopep-
tide agents (rules 12.1–12.6). For enterococci, the evidence
for these rules is graded A or B and is based on clinical data
[73,74]. For staphylococci, however, the evidence for most
rules is graded C, owing to microbiological demonstration of
the absence of in vitro synergy of the aminoglycosides with
cell wall-active compounds, even with isolates that are appar-
ently susceptible to aminoglycosides [75,76].
In Gram-negative organisms, EUCAST interpretive rules
for aminoglycosides tend to change a susceptible or an inter-
mediate result to the resistant category (rules 12.7–12.10).
The evidence for all of these rules is graded C, and is mainly
based on biochemical data indicating that these compounds
are enzymatically affected. In most cases, the increase in MIC
values or decrease in inhibition zones is very small. Modiﬁca-
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tion of results to the resistant category avoids clinical use of
these compounds [77–80].
In certain Gram-negative organisms, such as Providencia
stuartii (but not Providencia rettgerii) and Serratia marcescens,
the aminoglycoside-modifying enzymes are chromosomally
encoded and are weakly expressed. However, as mutational
events confer phenotypic resistance, these isolates should be
considered to be (intrinsically) resistant to these agents
(Table 1, rules 1.12 and 1.14) [81–83]. E. faecium intrinsically
produces a chromosomal aminoglycoside-modifying enzyme
that is also responsible for loss of synergy between certain
aminoglycosides and cell wall-active compounds (Table 4,
rule 4.8) [84].
Interpretive rules for quinolones
The quinolone agents are rapidly bactericidal within a range
of concentrations, and when that range is exceeded the
lethal action is diminished [85]. The quinolones interact with
bacterial type II topoisomerase DNA gyrases encoded by
gyrA and gyrB and topoisomerase IV encoded by parC and
parE (in staphylococci, grlA and grlB), which are the preferen-
tial targets of Gram-negative and Gram-positive organisms,
respectively. Topoisomerase mutations in gyrA and parC and
reduction in target access, including porin modiﬁcation and
efﬂux systems, are the classical chromosomally encoded
mechanisms affecting these compounds. Topoisomerase
mutations can confer high-level resistance, mainly through
stepwise selection of several mutations in the same or differ-
ent topoisomerase [86].
Plasmid-mediated quinolone resistance mechanisms have
emerged in Gram-negative bacilli during the last decades, and
are now frequently observed in many parts of the world
[87]. All of them demonstrate low expression, and they do
not always affect all ﬂuoroquinolone agents. Target protec-
tion mechanisms involving the Qnr proteins were the ﬁrst
described plasmid-mediated resistance mechanisms [88]. Sev-
eral families of these proteins have now been described,
mainly in Enterobacteriaceae. In addition, enzymatic modiﬁca-
tion involving a mutated aminoglycoside-modifying enzyme
and also affecting only certain ﬂuoroquinolones has been
identiﬁed in these organisms. This enzyme (AAC(6¢)-Ib-cr)
affects C7-piperazinyl substituted ﬂuoroquinolones, ciproﬂox-
acin, and norﬂoxacin, but not levoﬂoxacin [89]. More
recently, two plasmid-mediated efﬂux-based mechanisms
involving the QepA and OqxAB pumps related to major
facilitator superfamily transporters have been described. In
this case, the resistance is low-level and phenotypic detec-
tion is extremely difﬁcult [90,91].
In general, older quinolones have lower activity than more
recently developed agents. This is more obvious with Gram-
negative organisms, and is particularly evident in Enterobacte-
riaceae. However, particularly with resistance caused by
mutations in topoisomerases, decreased susceptibility to one
ﬂuoroquinolone is reﬂected in reduced susceptibility to
other ﬂuoroquinolones (class resistance). With these iso-
lates, the concomitant presence of different mutations
increases the level of ﬂuoroquinolone resistance. Neverthe-
less, Qnr protein, efﬂux and enzymatic modiﬁcation resis-
tance mechanisms may not confer resistance to all
ﬂuoroquinolones. Such low-level resistance mechanisms are
difﬁcult to detect, but they indicate the potential for selec-
tion of higher-level resistance mechanisms.
When antibiograms with quinolones are read, resistance
to the most active ﬂuoroquinolone in vitro indicates resis-
tance to all ﬂuoroquinolones in both Gram-negative and
Gram-positive organisms [92–94]. An exception to this rule
in Gram-negative organisms is the potential production of
the AAC(6¢)-Ib-cr enzyme, which affects ciproﬂoxacin but
not levoﬂoxacin. EUCAST interpretive rules for ﬂuoroquinol-
ones (rules 13.2, 13.4, 13.5, 13.6, and 13.8) all take this
approach, supported by different levels of evidence (grades B
or C). In some organisms (i.e. Enterobacteriaceae and H. inﬂu-
enzae), nalidixic acid can be used as a predictor of resistance
mechanisms affecting ﬂuoroquinolones [95–97]. However, in
Enterobacteriaceae this compound does not detect qnr-medi-
ated or other plasmid-mediated quinolone resistance, which
is increasingly being recognized all over the world. For this
reason, in this second version of the expert rules, modiﬁca-
tion of ﬂuoroquinolone susceptibility results on the basis of
ciproﬂoxacin MIC values is recommended for Salmonella
spp., as there is clear clinical evidence for ciproﬂoxacin
indicating a poor response in systemic infections caused by
Salmonella spp. with low-level quinolone resistance
(MIC >0.064 mg/L) (rule 13.6). The available data relate
mainly to Salmonella Typhi, but there are also case reports of
poor response with other Salmonella species [95,97,98]. On
the contrary, rule 13.6 does not apply to other Enterobacteri-
aceae, as there is a lack of such clear clinical evidence and
generalization cannot be recommended. Nevertheless, labo-
ratories might alert clinicians to the possibility of emergence
of high-level resistance to ﬂuoroquinolones in Enterobacteria-
ceae with low-level resistance to these compounds when
ﬂuoroquinolones are used.
In staphylococci and viridans group streptococci, resis-
tance to the less active, but not to the more active, ﬂuor-
oquinolones indicates that a ﬁrst-step mutation may be
present. In this case, a warning should be added to the sus-
ceptibility testing report, alerting clinicians to the potential
for selection of a higher-level resistance mechanism involving
different mutations (rules 13.1 and 13.3).
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Inference of speciﬁc ﬂuoroquinolone resistance mecha-
nisms can be difﬁcult in multidrug-resistant organisms, as
they may have superimposed mechanisms affecting these
compounds (low-level and/or high-level resistance). More-
over, with any of the new plasmid-mediated resistance mech-
anisms, there is little possibility of interpretive reading. In
some cases, a slight decrease in susceptibility to all quinol-
ones is observed, but in others a greater decrease in suscep-
tibility to ﬂuoroquinolones than that observed with nalidixic
acid can be seen [89–91].
Future of Expert Rules and Concluding
Remarks
Expert rules were designed to assist clinical microbiologists
in the interpretation of antimicrobial susceptibility testing
results. The main objective of these rules has been to modify
the clinical interpretation after application of clinical break-
point criteria. In most instances, susceptible or intermediate
clinical interpretations are modiﬁed to resistant, owing to
the demonstration of the presence of a resistance mecha-
nism that has clinical implications. These modiﬁcations are
supported by clinical evidence and/or microbiological knowl-
edge. Modiﬁcations can also imply, according to the deﬁni-
tion of clinical breakpoints, that the breakpoints used are
not optimal and thus require the support of an expert rule.
The current EUCAST process allows for revision of clini-
cal breakpoints. Revised breakpoints can be shown to be
more precise in the correlation of MIC values with expected
clinical outcomes. Setting appropriate clinical breakpoints
may make some of the previously deﬁned expert rules
unnecessary, as well as resulting in modiﬁcation or reword-
ing of other rules. This has been the case for the ESBL
expert rule, which is no longer necessary when the revised
cephalosporin breakpoints are used.
Finally, it is necessary to stress that clinical breakpoints, as
deﬁned by EUCAST, do not aim to detect all resistance mecha-
nisms that might be present in the bacteria. Rather, they have
been developed to predict the outcome of antimicrobial treat-
ment of infected patients on the basis of microbiological, PK/PD
and clinical criteria. It is also important to note that EUCAST
expert rules should be used with EUCAST breakpoints, and
may not be applicable if other breakpoint systems are used.
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